Article

Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – an Exploratory Analysis of the Proxa-Rescue AndroCoV Trial

2021-07-02

Abstract excerpt

<h4>Introduction</h4> Proxalutamide, a second-generation non-steroidal antiandrogen (NSAA), primarily developed for castration-resistant prostate cancer, demonstrated reduction in 28-day mortality rate of 77.7% in hospitalized COVID-19 patients in a double-blind, placebo-controlled, two-arm randomized clinical trial (RCT), through intention-to-treat (ITT) analysis. We observed a high 28-day mortality rate of patie...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 544a7267-0314-523a-a321-b2b3fe532a55
DOI: 10.1101/2021.06.28.21259661

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Proxalutamide Reduction of Mortality Rate in Hospitalized COVID-19 Patients Depends on Treatment Duration – an Exploratory Analysis of the Proxa-Rescue AndroCoV TrialDOI 10.1101/2021.06.28.21259661Read

Progesterone in Addition to Standard of Care Versus Standard of Care Alone in the Treatment of Men Admitted to the Hospital with Moderate to Severe COVID-19: A Randomised Control Phase 1 TrialSemantic proximity Read

Use of Antiandrogens as Therapeutic Agents in COVID-19 PatientsSemantic proximity Read

NSAIDs and Kelleni’s protocol as potential early COVID-19 treatment game changer: could it be the final countdown?Semantic proximity Read

‘Which severe COVID-19 patients could benefit from High dose dexamethasone? A Bayesian reanalysis of a randomized clinical trialSemantic proximity Read

Lack of precision in the reporting of sex and gender in cancer clinical trials with a PRO endpoint: a systematic reviewSemantic proximity Read

Apalutamide Monotherapy in Metastatic Hormone-Sensitive Prostate Cancer: a Viable Alternative to First Generation Anti-Androgen Agents to Avoid the Flare Phenomenon and an Effective Treatment to Achieve Early PSA ResponseSemantic proximity Read

Ruxolitinib Versus Dexamethasone in Hospitalized Adults With COVID-19: Multicenter Matched Cohort StudySemantic proximity Read

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.Semantic proximity Read

COVIDENZA - A Prospective, Multicenter, Randomized PHASE II Clinical Trial of Enzalutamide Treatment to Decrease the Morbidity in Patients with Corona Virus Disease 2019 (COVID-19)Semantic proximity Read

A Systematic Review of Sex Differences in Postoperative Nausea and VomitingSemantic proximity Read

Bovhyaluronidase azoximer for long-term pulmonary sequelae of COVID-19: a randomized, double-blind, placebo-controlled trialSemantic proximity Read

Skin Rash Following Administration of Apalutamide in Japanese Patients with Advanced Prostate Cancer: An Integrated Analysis of the Phase 3 SPARTAN and TITAN Studies and a Phase 1 Open-Label StudySemantic proximity Read